Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025:2962:237-253.
doi: 10.1007/978-1-0716-4726-4_16.

Knockdown of Gene Expression Following Activation of the NMD Pathway Using Splice-Switching Oligonucleotides

Pierre Hirt  1 , Anne Marchalot  2   3 , Catherine Horiot  2 , Jérôme Moreaux  4 , Laurent Delpy  5
Affiliations

Knockdown of Gene Expression Following Activation of the NMD Pathway Using Splice-Switching Oligonucleotides

Pierre Hirt et al. Methods Mol Biol. 2025.

Abstract

Antisense oligonucleotides (ASOs) are commonly used to induce transient changes in gene expression and do not result in mutagenic effects at the DNA level. In this chapter, we describe a novel gene silencing approach using splice-switching oligonucleotides (SSOs) capable of hybridizing at a splice site to induce exon skipping. This strategy is based on the elimination of an exon whose nucleotide length is not a multiple of 3. In this way, exon skipping induces a frameshift in the reading frame and the appearance of a premature termination codon (PTC) on the alternative transcript. After detection of the PTC, alternative transcripts are degraded by the NMD pathway. Here, we present the steps involved in the SSO design, cell treatment, and assessment of gene silencing. We provide evidence for efficient knockdown of Enhancer of Zeste Homolog 2 (EZH2) expression in lymphoid cells.

Keywords: Antisense oligonucleotide (ASO); Enhancer of Zeste Homolog 2 (EZH2); Exon skipping; Gene silencing; Knockdown; Nonsense-mediated mRNA decay (NMD); Splice-switching oligonucleotide (SSO).

PubMed Disclaimer

References

    1. Bennett CF (2019) Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med 70:307–321. https://doi.org/10.1146/annurev-med-041217-010829 - DOI - PubMed
    1. Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 19:673–694. https://doi.org/10.1038/s41573-020-0075-7 - DOI - PubMed - PMC
    1. Zammarchi F, de Stanchina E, Bournazou E, Supakorndej T, Martires K, Riedel E, Corben AD, Bromberg JF, Cartegni L (2011) Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci USA 108:17779–17784. https://doi.org/10.1073/pnas.1108482108 - DOI - PubMed - PMC
    1. Marchalot A, Lambert J-M, Boyer F, Pollet J, Moreau J, Feuillard J, Faumont N, Delpy L (2020) Splice switching oligonucleotide mediated gene knockdown in B cells and plasma cells. 2020.09.18.302984
    1. Lejeune F, Maquat LE (2005) Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. Curr Opin Cell Biol 17:309–315. https://doi.org/10.1016/j.ceb.2005.03.002 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources